Tetraphase Pharmaceuticals Selects SHYFT to Support Data and Analytics for Commercial Launch Readiness
WALTHAM, Mass., July 17, 2018 /PRNewswire/ -- SHYFT Analytics, recently acquired by Medidata Solutions to create the only Intelligent Platform for Life Sciences, announced Tetraphase Pharmaceuticals has selected its platform to support the anticipated commercial launch of eravacycline, its lead antibiotic candidate developed to address multidrug-resistant bacteria. The launch is subject to approval by regulatory authorities. With its scalable cloud platform, SHYFT will empower Tetraphase with novel analytics that provide comprehensive market intelligence and commercial insights to meet commercialization milestones and help drive a successful drug launch.
According to the Centers for Disease and Control (CDC), approximately two million Americans contract infections from antibiotic-resistant bacteria each year. Tetraphase Pharmaceuticals has leveraged its proprietary, fully-synthetic chemistry technology to develop a pipeline of innovative antibiotics with unique profiles that have the potential to improve the treatment of serious bacterial infections.
Eravacycline is currently being developed for the treatment of complicated intra-abdominal infections (cIAI). Pending a decision by the U.S. Food and Drug Administration, Tetraphase plans to launch the broad-spectrum antibiotic in the U.S. later in 2018. As part of that potential launch, Tetraphase will use the Intelligent Platform for Life Sciences to effectively integrate their numerous data sources and create a holistic view of the relevant clinical and commercial information - enabling insights into various areas, including payer needs and the patient journey.
"This is a pivotal time for Tetraphase, as we prepare to launch our first commercial product pending approval by the FDA. Ensuring we have the insights and analytics necessary to have a successful launch is critical," said Larry Edwards, Chief Operating Officer at Tetraphase. "SHYFT's right-sized and scalable approach, combined with their deep expertise in helping specialty pharma brands successfully and quickly derive insights, will help us better address physician and patient needs, meet commercial milestones, and ensure we can scale to surpass our launch goals."
"Addressing the increase in antibiotic resistance relies on effective novel therapies like Tetraphase's eravacycline," said Zack King, EVP Medidata, President of SHYFT. "A product's success in this therapeutic area requires a thorough understanding of the market, patients, and unique differentiators. We're honored to partner with the Tetraphase team on an innovative approach to data analytics to ensure that new and life-changing therapies have the opportunity to thrive in an ever-changing, complex market. This is core to SHYFT's mission."
About SHYFT
SHYFT Analytics, a Medidata company, is the leading platform for commercial and real-world data analytics with products designed specifically for the pharmaceutical, biotech, and medical device industry. SHYFT's data analytics platform is the most efficient and scalable way to transform massive amounts of complex healthcare data into on-demand clinical and commercial insight. SHYFT is headquartered in Boston with offices in San Francisco and New York City. Learn more about SHYFT at www.shyftanalytics.com, or follow the company on Twitter @SHYFTAnalytics or LinkedIn.
About Medidata
Medidata is leading the digital transformation of life sciences, with the world's most used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by the #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata serves more than 1,000 customers and partners worldwide and empowers more than 100,000 certified users everyday to create hope for millions of patients. Discover the future of life sciences: www.mdsol.com
View original content with multimedia:http://www.prnewswire.com/news-releases/tetraphase-pharmaceuticals-selects-shyft-to-support-data-and-analytics-for-commercial-launch-readiness-300681796.html
SOURCE SHYFT Analytics
